凝血障碍-话题@MedSci

#凝血障碍#

10篇内容 | 1196人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2220357, encodeId=5451222035e8b, content=<a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a> 血管性血友病(VWD)患者因血管性血友病因子(VWF)缺陷和/或缺陷而有出血倾向增加的症状。VWD的治疗取决于VWD的类型、预先存在的因子VIII(FVIII)水平、VWF活性水平和临床参数/特征，患者围手术期需给予血管性血友病因子(VWF)浓缩液。考虑到反复注射1:1比例的VWF/FVIII凝血因子浓缩液(CFC)后FVIII积累的问题，这项研究主要探讨了恢复和FVIII积累随时间的变化。, objectTitle=凝血障碍, objectType=topic, longId=31349, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=10, createdTime=2024-08-15, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2220301, encodeId=3aa3222030162, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a> <a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a> <a href='/topic/show?id=9b438964ebb' target=_blank style='color:#2F92EE;'>#血管性血友病#</a> <a href='/topic/show?id=cdea11e936a8' target=_blank style='color:#2F92EE;'>#VWF/FVIII 复合物#</a>, objectTitle=Haemophilia：1：1 比例的 VWF/FVIII 复合物对血管性血友病患者的疗效, objectType=article, longId=839058, objectId=5f4583905876, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240612/1718183341497_92910.jpg, objectUrl=/article/show_article.do?id=5f4583905876, replyNumber=0, likeNumber=82, createdTime=2024-08-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5f4583905876, moduleTitle=Haemophilia：1：1 比例的 VWF/FVIII 复合物对血管性血友病患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f4583905876)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1557328, encodeId=0a6d155e32864, content=<a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a>, objectTitle=Stroke ：凝血障碍导致的脑出血，andexanet alfa治疗并未改变临床预后, objectType=article, longId=218793, objectId=b0c4218e93f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0c4218e93f9, replyNumber=0, likeNumber=88, createdTime=2021-10-19, rootId=0, userName=millore, userId=22d514907598, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0c4218e93f9, moduleTitle=Stroke ：凝血障碍导致的脑出血，andexanet alfa治疗并未改变临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0c4218e93f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1557327, encodeId=2b87155e327a3, content=<a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a>, objectTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, objectType=article, longId=203477, objectId=04852034e7dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04852034e7dd, replyNumber=0, likeNumber=73, createdTime=2020-11-18, rootId=0, userName=millore, userId=22d514907598, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04852034e7dd, moduleTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04852034e7dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1557326, encodeId=d59a155e326c7, content=<a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a>, objectTitle=JAMA：凝血障碍与腰椎穿刺术后脊髓血肿风险, objectType=article, longId=202120, objectId=adeb20212087, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adeb20212087, replyNumber=0, likeNumber=71, createdTime=2020-10-16, rootId=0, userName=millore, userId=22d514907598, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adeb20212087, moduleTitle=JAMA：凝血障碍与腰椎穿刺术后脊髓血肿风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adeb20212087)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1557325, encodeId=14c0155e32531, content=<a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a>, objectTitle=J Thromb Haemost：重组人可溶性血栓调节蛋白对脓毒症相关凝血障碍患者中的疗效和安全性 , objectType=article, longId=191574, objectId=045e1915e4d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=045e1915e4d7, replyNumber=0, likeNumber=71, createdTime=2020-04-08, rootId=0, userName=millore, userId=22d514907598, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=045e1915e4d7, moduleTitle=J Thromb Haemost：重组人可溶性血栓调节蛋白对脓毒症相关凝血障碍患者中的疗效和安全性 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=045e1915e4d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1557324, encodeId=00fb155e32460, content=<a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a>, objectTitle=Blood：乙酰水杨酸预防感染相关凝血障碍和组织损伤, objectType=article, longId=186570, objectId=8fd61865e08f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fd61865e08f, replyNumber=0, likeNumber=79, createdTime=2020-01-21, rootId=0, userName=millore, userId=22d514907598, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fd61865e08f, moduleTitle=Blood：乙酰水杨酸预防感染相关凝血障碍和组织损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fd61865e08f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1557323, encodeId=69d9155e3236c, content=<a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a>, objectTitle=2019 欧洲指南：严重创伤出血和凝血障碍的管理（第5版）, objectType=article, longId=164447, objectId=54c016444e99, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54c016444e99, replyNumber=0, likeNumber=64, createdTime=2019-04-18, rootId=0, userName=millore, userId=22d514907598, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54c016444e99, moduleTitle=2019 欧洲指南：严重创伤出血和凝血障碍的管理（第5版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54c016444e99)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1557322, encodeId=0f0b155e322ef, content=<a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a>, objectTitle=纳米抗体药Cablivi获FDA批准治疗罕见凝血障碍, objectType=article, longId=160608, objectId=68541606084c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68541606084c, replyNumber=0, likeNumber=80, createdTime=2019-02-22, rootId=0, userName=millore, userId=22d514907598, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68541606084c, moduleTitle=纳米抗体药Cablivi获FDA批准治疗罕见凝血障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68541606084c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1557321, encodeId=1bf4155e321a5, content=<a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a>, objectTitle=JACC：经皮导管主动脉瓣置换术后原发性凝血障碍和主要出血并发症, objectType=article, longId=152332, objectId=73301523327e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73301523327e, replyNumber=0, likeNumber=99, createdTime=2018-11-01, rootId=0, userName=millore, userId=22d514907598, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73301523327e, moduleTitle=JACC：经皮导管主动脉瓣置换术后原发性凝血障碍和主要出血并发症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73301523327e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1557320, encodeId=23d6155e320ad, content=<a href='/topic/show?id=cf11313491c' target=_blank style='color:#2F92EE;'>#凝血障碍#</a>, objectTitle=NEJM：探讨重症监护中出血与凝血障碍, objectType=article, longId=31413, objectId=01ae314135d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01ae314135d, replyNumber=0, likeNumber=81, createdTime=2014-03-05, rootId=0, userName=millore, userId=22d514907598, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01ae314135d, moduleTitle=NEJM：探讨重症监护中出血与凝血障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01ae314135d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

凝血障碍

2020-05-29

yangchou (审核中...)

前往app查看评论内容

全文收起 #凝血障碍# 血管性血友病(VWD)患者因血管性血友病因子(VWF)缺陷和/或缺陷而有出血倾向增加的症状。VWD的治疗取决于VWD的类型、预先存在的因子VIII(FVIII)水平、VWF活性水平和临床参数/特征，患者围手术期需给予血管性血友病因子(VWF)浓缩液。考虑到反复注射1:1比例的VWF/FVIII凝血因子浓缩液(CFC)后FVIII积累的问题，这项研究主要探讨了恢复和FVIII积累随时间的变化。

2024-08-15发表于浙江省

梅斯管理员 (审核中...)

前往app查看评论内容

#血液学# #凝血障碍# #血管性血友病# #VWF/FVIII 复合物#

Haemophilia：1：1 比例的 VWF/FVIII 复合物对血管性血友病患者的疗效

2024-08-15发表于上海

millore (审核中...)

前往app查看评论内容

#凝血障碍#

Stroke ：凝血障碍导致的脑出血，andexanet alfa治疗并未改变临床预后

2021-10-19

millore (审核中...)

前往app查看评论内容

#凝血障碍#

全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍

2020-11-18

millore (审核中...)

前往app查看评论内容

#凝血障碍#

JAMA：凝血障碍与腰椎穿刺术后脊髓血肿风险

2020-10-16

millore (审核中...)

前往app查看评论内容

#凝血障碍#

J Thromb Haemost：重组人可溶性血栓调节蛋白对脓毒症相关凝血障碍患者中的疗效和安全性

2020-04-08

millore (审核中...)

前往app查看评论内容

#凝血障碍#

Blood：乙酰水杨酸预防感染相关凝血障碍和组织损伤

2020-01-21

millore (审核中...)

前往app查看评论内容

#凝血障碍#

2019 欧洲指南：严重创伤出血和凝血障碍的管理（第5版）

2019-04-18

millore (审核中...)

前往app查看评论内容

#凝血障碍#

纳米抗体药Cablivi获FDA批准治疗罕见凝血障碍

2019-02-22

millore (审核中...)

前往app查看评论内容

#凝血障碍#

JACC：经皮导管主动脉瓣置换术后原发性凝血障碍和主要出血并发症

2018-11-01

millore (审核中...)

前往app查看评论内容

#凝血障碍#

NEJM：探讨重症监护中出血与凝血障碍

2014-03-05

科室
- - 订阅+
  - 更多科室
工具
服务